View More Recent Stories
-
Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy
-
Nektar Therapeutics (NKTR) Files $300M Mixed Shelf
-
Oppenheimer Upgrades Nektar Therapeutics (NKTR) to Outperform
-
BTIG Reiterates Neutral Rating on Nektar Therapeutics (NKTR)
-
Nektar Therapeutics (NKTR) PT Lowered to $1 at Jefferies
-
Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c
-
Nektar Therapeutics (NKTR) Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin
-
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR)
-
Piper Sandler Reiterates Overweight Rating on Nektar Therapeutics (NKTR)
-
Nektar Therapeutics (NKTR) Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
-
Nektar Therapeutics (NKTR) Receives Fast Track Designation for Rezpegaldesleukin
-
Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study
-
B.Riley Starts Nektar Therapeutics (NKTR) at Buy
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
H.C. Wainwright Starts Nektar Therapeutics (NKTR) at Buy
-
Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c
-
Nektar Therapeutics (NKTR) and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255
-
Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama
-
Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight
-
Nektar Therapeutics (NKTR) Announces Publication of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
-
Nektar Therapeutics (NKTR) Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy
-
BTIG Assumes Nektar Therapeutics (NKTR) at Buy
-
Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c
-
Nektar Therapeutics (NKTR) Presents First Preclinical Data on NKTR-0165

